PWM
SUPN icon

Perigon Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Perigon Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,270
Closed -$32K – 965
2020
Q4 		$32K Buy
+1,270
New +$27.3K ﹤0.01% 885
2018
Q2 		– Sell
-1,674
Closed -$77K – 546
2018
Q1 		$77K Hold
1,674
– – 0.03% 263
2017
Q4 		$67K Hold
1,674
– – 0.03% 254
2017
Q3 		$67K Buy
+1,674
New +$72.4K 0.02% 303

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Perigon Wealth Management's SUPN Position: Q1 2021 in Review

Perigon Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2021, closing a stake of 1,270 shares — an estimated $32K sold.

Perigon Wealth Management first reported a position in SUPN in Q3 2017 and held it in 4 quarters. The position peaked at $77K in Q1 2018. 224 funds tracked by Wall St. Rank hold SUPN as of Q1 2021.

  • Perigon Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Perigon Wealth Management sold 1,270 Supernus Pharmaceuticals shares in Q1 2021, an estimated $32K.
  • Perigon Wealth Management first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 4 quarters.
  • Perigon Wealth Management's Supernus Pharmaceuticals position peaked at $77K in Q1 2018.
  • 224 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2021.

Based on Perigon Wealth Management's 13F filing for Q1 2021, filed 17 May 2021.